Hyperfine (HYPR) Asset Writedowns and Impairment (2021)

Hyperfine's (HYPR) quarterly Asset Writedowns and Impairment came in at $56000.0 in Q4 2021, up 500.0% on a QoQ basis from -$14000.0 in Q3 2021.

Hyperfine (HYPR) Asset Writedowns and Impairment (2021) Analysis & Trends

Hyperfine (HYPR) has 1 years of Asset Writedowns and Impairment data on file, last reported at $56000.0 in Q4 2021.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $56000.0 in Q4 2021, while the trailing twelve-month figure through Sep 2022 was $56000.0 (changed N/A YoY) and the FY2021 annual result came in at $75000.0, down 64.79% from the prior year.
Asset Writedowns and Impairment improved to $56000.0 in Q4 2021, from -$14000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $75000.0 in Q1 2021 to a low of -$42000.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn
10	Hyperfine	90.12 Mn	45.35 Mn	1.98 Mn

Download Data